Resmed will release its Q1 fiscal year 2026 results on October 30, 2025, followed by a management webcast.
Quiver AI Summary
ResMed announced that it will release its financial and operational results for the first quarter of fiscal year 2026 on October 30, 2025, after the NYSE closes. Following the release, the company's management will conduct a webcast to discuss the results and potentially other forward-looking information. The webcast will be available on ResMed's investor relations website at 1:30 p.m. PDT, with international times noted for London and Sydney. Access to the earnings call will be via the provided webcast link only, with a replay available on the website shortly after. ResMed focuses on innovative health technologies that enhance the lives of people worldwide, promoting better sleep and breathing through advanced digital health solutions.
Potential Positives
- Resmed is set to announce financial and operational results for Q1 fiscal year 2026, which signals the company's ongoing commitment to transparency and regular communication with stakeholders.
- The planned webcast following the earnings release provides investors and interested parties with an opportunity to gain insights directly from management, showcasing Resmed's proactive engagement with its investor community.
- The company's focus on innovative health technologies reflects its mission to improve healthcare outcomes, positioning Resmed as a leader in the health tech industry.
Potential Negatives
- The announcement does not provide any preliminary financial information or highlights, which may lead to speculation about a potentially poor performance in the upcoming quarter.
- The limited details about the earnings call format (only available via webcast, no phone access) could alienate some investors who prefer traditional access methods, potentially affecting participation.
- Failure to recognize or address any current challenges or issues within the company may lead stakeholders to question transparency or the overall health of the organization.
FAQ
When will Resmed announce its Q1 fiscal 2026 results?
Resmed plans to release its financial and operational results on Thursday, October 30, 2025, after NYSE closes.
How can I access the Resmed earnings webcast?
The earnings webcast can be accessed at https://investor.resmed.com on October 30, 2025, at 1:30 p.m. PDT.
Will there be a replay of the earnings webcast?
Yes, a replay of the earnings webcast will be available approximately two hours after the event on Resmed’s investor relations website.
What time is the webcast for international viewers?
The webcast will be at 8:30 p.m. GMT in London and 7:30 a.m. AEDT in Sydney on October 31, 2025.
How can investors contact Resmed for more information?
Investors can reach Resmed at +1 858.221.3304 or via email at [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RMD Congressional Stock Trading
Members of Congress have traded $RMD stock 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $RMD stock by members of Congress over the last 6 months:
- REPRESENTATIVE KELLY MORRISON has traded it 5 times. They made 0 purchases and 5 sales worth up to $75,000 on 06/04, 04/28.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$RMD Insider Trading Activity
$RMD insiders have traded $RMD stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $RMD stock by insiders over the last 6 months:
- MICHAEL J. FARRELL (Chief Executive Officer) has made 0 purchases and 6 sales selling 48,054 shares for an estimated $12,747,290.
- BRETT SANDERCOCK (Chief Financial Officer) has made 0 purchases and 6 sales selling 17,527 shares for an estimated $4,614,048.
- PETER C FARRELL has made 0 purchases and 3 sales selling 4,945 shares for an estimated $1,220,578.
- JOHN HERNANDEZ sold 2,575 shares for an estimated $739,289
- WITTE JAN DE sold 2,000 shares for an estimated $486,940
- MICHAEL J RIDER (Global General Counsel) has made 0 purchases and 3 sales selling 157 shares for an estimated $41,051.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RMD Hedge Fund Activity
We have seen 454 institutional investors add shares of $RMD stock to their portfolio, and 397 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY removed 1,479,378 shares (-35.7%) from their portfolio in Q2 2025, for an estimated $381,679,524
- NORGES BANK added 669,170 shares (+129.0%) to their portfolio in Q2 2025, for an estimated $172,645,860
- OVERSEA-CHINESE BANKING CORP LTD removed 547,532 shares (-92.7%) from their portfolio in Q2 2025, for an estimated $141,263,256
- MARSHALL WACE, LLP removed 543,857 shares (-97.7%) from their portfolio in Q2 2025, for an estimated $140,315,106
- CONGRESS ASSET MANAGEMENT CO removed 484,773 shares (-99.0%) from their portfolio in Q2 2025, for an estimated $125,071,434
- CITADEL ADVISORS LLC added 328,864 shares (+853.5%) to their portfolio in Q2 2025, for an estimated $84,846,912
- SQUAREPOINT OPS LLC added 311,536 shares (+132.7%) to their portfolio in Q2 2025, for an estimated $80,376,288
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RMD Analyst Ratings
Wall Street analysts have issued reports on $RMD in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 09/18/2025
- Mizuho issued a "Outperform" rating on 08/01/2025
- RBC Capital issued a "Outperform" rating on 08/01/2025
- UBS issued a "Buy" rating on 08/01/2025
- JP Morgan issued a "Overweight" rating on 04/24/2025
- Keybanc issued a "Overweight" rating on 04/24/2025
To track analyst ratings and price targets for $RMD, check out Quiver Quantitative's $RMD forecast page.
$RMD Price Targets
Multiple analysts have issued price targets for $RMD recently. We have seen 9 analysts offer price targets for $RMD in the last 6 months, with a median target of $290.0.
Here are some recent targets:
- Laura Sutcliffe from Citigroup set a target price of $330.0 on 09/18/2025
- Brett Fishbin from Keybanc set a target price of $298.0 on 08/01/2025
- Adam Maeder from Piper Sandler set a target price of $270.0 on 08/01/2025
- Jonathan Block from Stifel set a target price of $270.0 on 08/01/2025
- Craig Wong-Pan from RBC Capital set a target price of $300.0 on 08/01/2025
- Laura Sutcliffe from UBS set a target price of $325.0 on 08/01/2025
- Anthony Petrone from Mizuho set a target price of $290.0 on 08/01/2025
Full Release
SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2026 on Thursday, October 30, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
Earnings webcast details:
| • | Location: | https://investor.resmed.com | |
| • | Date: | Thursday, October 30, 2025 | |
| • | Time: | 1:30 p.m. PDT / 4:30 p.m. EDT | |
| • | International: |
London, Thursday, October 30, 2025, 8:30 p.m. GMT
Sydney, Friday, October 31, 2025, 7:30 a.m. AEDT |
|
Please note, Resmed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only.
A replay of the earnings webcast will be accessible on Resmed’s investor relations website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately three hours after the webcast and will be accessible from October 30, 2025, until November 13, 2025, at:
| • | U.S.: +1 877.660.6853 | |
| • | International: +1 201.612.7415 | |
| • | Conference ID: 13756529 | |
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
|
For investors
+1 858.221.3304 [email protected] |
For media
+1 619.510.1281 [email protected] |
